Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ALNY

ALNY - Alnylam Pharmaceuticals Inc Stock Price, Fair Value and News

149.38USD-1.84 (-1.22%)Delayed

Market Summary

ALNY
USD149.38-1.84
Delayed
-1.22%

ALNY Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

ALNY Stock Price

View Fullscreen

ALNY RSI Chart

ALNY Valuation

Market Cap

18.9B

Price/Earnings (Trailing)

-56.9

Price/Sales (Trailing)

9.43

EV/EBITDA

-129.93

Price/Free Cashflow

147.82

ALNY Price/Sales (Trailing)

ALNY Profitability

EBT Margin

-16.21%

Return on Equity

151.44%

Return on Assets

-8.68%

Free Cashflow Yield

0.68%

ALNY Fundamentals

ALNY Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

54.82%

Rev. Growth (Qtr)

12.42%

ALNY Earnings

Earnings (TTM)

-332.1M

Earnings Growth (Yr)

62.13%

Earnings Growth (Qtr)

52.18%

Breaking Down ALNY Revenue

Last 7 days

-0.7%

Last 30 days

2.8%

Last 90 days

1.6%

Trailing 12 Months

-21.3%

How does ALNY drawdown profile look like?

ALNY Financial Health

Current Ratio

3.17

Debt/Equity

-4.66

Debt/Cashflow

0.19

ALNY Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-2.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0B000
20231.1B1.2B1.7B1.8B
2022880.0M884.2M960.9M1.0B
2021570.9M687.5M749.3M844.3M
2020285.9M345.2M401.0M492.9M
201986.3M101.1M169.1M219.8M
201892.9M106.8M91.8M74.9M
201758.8M66.0M69.4M89.9M
201629.9M29.9M37.3M47.2M
201560.8M62.2M57.6M41.1M
201436.8M35.4M37.4M50.6M
201364.8M52.6M44.8M47.2M
201282.4M82.7M78.7M66.7M
201196.4M90.4M83.5M82.8M
2010100.0M102.1M105.5M100.0M
2009097.6M99.1M100.5M
200800096.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alnylam Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 01, 2024
tanguler tolga
acquired
-
-
4,751
evp, chief commercial officer
Mar 01, 2024
greenstreet yvonne
acquired
-
-
23,754
chief executive officer
Mar 01, 2024
garg pushkal
acquired
-
-
4,751
cmo & evp dev & med affairs
Mar 01, 2024
poulton jeffrey v.
acquired
-
-
7,741
evp, chief financial officer
Feb 29, 2024
sharp phillip a
sold
-4,540,070
151
-30,000
-
Feb 29, 2024
sharp phillip a
acquired
1,777,500
59.25
30,000
-
Feb 28, 2024
greenstreet yvonne
sold
-455,357
155
-2,932
chief executive officer
Feb 28, 2024
tanguler tolga
sold
-77,805
155
-501
evp, chief commercial officer
Feb 28, 2024
garg pushkal
sold
-89,144
155
-574
cmo & evp dev & med affairs
Feb 28, 2024
franchini indrani lall
sold
-51,094
155
-329
evp, clo & secretary

1–10 of 50

Which funds bought or sold ALNY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
FSA Wealth Management LLC
unchanged
-
-804
1,196
-%
May 16, 2024
Semmax Financial Advisors Inc.
unchanged
-
-169
2,099
-%
May 16, 2024
COMERICA BANK
reduced
-2.69
-614,266
1,943,320
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-0.08
-8,062,520
28,607,400
0.04%
May 16, 2024
Tidal Investments LLC
added
292
1,034,810
1,536,500
0.03%
May 16, 2024
Motley Fool Asset Management LLC
reduced
-3.69
-96,597
292,922
0.02%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-8,982,810
-
-%
May 16, 2024
JANE STREET GROUP, LLC
added
68.38
5,864,280
24,500,500
-%
May 15, 2024
PRELUDE CAPITAL MANAGEMENT, LLC
added
318
718,863
1,035,840
0.05%
May 15, 2024
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp
added
4.16
-514,032
2,239,210
0.01%

1–10 of 31

Are Funds Buying or Selling ALNY?

Are funds buying ALNY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALNY
No. of Funds

Unveiling Alnylam Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.52%
11,943,895
SC 13G/A
Feb 09, 2024
capital world investors
13.1%
16,398,889
SC 13G/A
Feb 09, 2024
wellington management group llp
5.78%
7,252,907
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
baillie gifford & co
5.55%
6,967,097
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
8,546,557
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
3.3%
4,074,144
SC 13G/A
Feb 13, 2023
capital world investors
13.5%
16,593,958
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.35%
11,507,116
SC 13G/A

Recent SEC filings of Alnylam Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 02, 2024
10-Q
Quarterly Report
May 02, 2024
8-K
Current Report
Apr 01, 2024
ARS
ARS
Apr 01, 2024
DEF 14A
DEF 14A
Apr 01, 2024
DEFA14A
DEFA14A
Mar 28, 2024
3
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Alnylam Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Alnylam Pharmaceuticals Inc News

Latest updates
Defense World23 hours ago
Yahoo New Zealand News14 May 202405:04 am

Alnylam Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue12.4%494,333,000439,718,000750,530,000318,754,000319,290,000335,035,000264,306,000224,818,000213,259,000258,535,000187,633,000220,553,000177,566,000163,562,000125,853,000103,962,00099,476,00071,681,00070,061,00044,714,00033,294,000
Costs and Expenses-3.3%537,768,000556,122,000536,663,000548,585,000469,097,000523,649,000522,346,000416,504,000359,991,000453,096,000369,310,000366,713,000363,820,000357,784,000351,052,000302,821,000309,634,000369,754,000286,360,000280,985,000222,082,000
  S&GA Expenses6.4%210,797,000198,123,000199,175,000214,689,000183,659,000210,344,000235,859,000169,984,000154,471,000186,382,000142,075,000145,323,000146,859,000166,291,000167,472,000127,896,000126,761,000156,277,000120,351,000112,769,00089,608,000
  R&D Expenses-4.1%260,995,000272,141,000253,179,000248,526,000230,569,000262,039,000245,371,000205,712,000169,893,000229,050,000194,572,000182,635,000185,899,000168,469,000161,783,000154,996,000169,571,000201,301,000160,796,000163,890,000129,127,000
EBITDA Margin47.7%-0.07-0.14-0.19-0.71-0.76-0.89-1.02-0.88-0.79-0.78-0.87-1.04---------
Interest Expenses-1.3%30,945,00031,338,00030,893,00030,035,00028,955,00029,913,00041,084,00042,609,00042,362,00036,816,00040,274,00033,416,00032,515,00028,517,00028,731,00027,248,000-----
Income Taxes1183.1%2,348,000183,0002,988,0001,815,0001,739,000472,000-23,0002,729,000985,000-1,842,000278,0001,228,0001,016,000-59,000839,0001,326,000575,000-398,000-394,000960,000695,000
Earnings Before Taxes53.8%-63,587,000-137,687,000150,741,000-274,209,000-172,362,000-207,021,000-405,943,000-274,673,000-239,356,000-260,302,000-204,236,000-188,331,000-199,275,000-243,599,000-252,452,000-177,903,000-181,646,000-276,583,000-208,929,000-218,521,000-181,220,000
EBT Margin31.6%-0.16-0.24-0.29-0.86-0.93-1.09-1.23-1.11-1.01-1.01-1.11-1.29---------
Net Income52.2%-65,935,000-137,870,000147,753,000-276,024,000-174,101,000-207,493,000-405,920,000-277,402,000-240,341,000-258,460,000-204,514,000-189,559,000-200,291,000-243,540,000-253,291,000-179,229,000-182,221,000-276,185,000-208,535,000-219,481,000-181,915,000
Net Income Margin31.2%-0.17-0.24-0.30-0.86-0.93-1.09-1.23-1.11-1.01-1.01-1.12-1.29---------
Free Cashflow-109.5%-94,488,000-45,104,000342,320,000-74,905,000-180,366,000-153,613,000-131,794,000-138,874,000-189,052,000-172,027,000-160,098,000-133,102,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.1%3,8243,8303,8393,4023,3923,5463,5353,3303,4343,6433,4723,5093,2553,4073,3073,3742,2802,3952,5422,7162,014
  Current Assets0.2%2,9892,9832,9852,5242,5412,6922,6912,4722,5902,8092,6752,7252,4702,6152,5552,1601,5851,7161,8972,0641,392
    Cash Equivalents-15.7%6858131,0336586728661,0735765348201,0947463804994975814685479231,136725
  Inventory5.4%94.0089.0096.0010013212911589.0079.0086.0098.0084.0074.0075.0067.0077.0068.0056.0055.0041.0032.00
  Net PPE-0.5%523526526527523523515508504502485471465465445439430425396372342
Liabilities-0.2%4,0444,0514,0053,8113,6513,7053,6033,1543,0323,0552,7162,6562,3292,3912,0921,975930956935959467
  Current Liabilities-2.7%942968950789673768773658606696611555495585480384339353353329149
  Long Term Debt0.1%1,0221,0211,0201,0191,0181,0171,016678677-434433192191-------
    LT Debt, Non Current-100.0%-1,0211,0201,0191,0181,0171,016--------------
Shareholder's Equity0.6%-219-220---259-158-1764015887568539261,0161,2151,4001,3501,4391,6071,7571,547
  Retained Earnings-0.9%-7,075-7,009-6,871-7,019-6,743-6,569-6,361-5,955-5,678-5,438-5,179-4,975-4,785-4,585-4,341-4,088-3,909-3,727-3,450-3,242-3,022
  Additional Paid-In Capital1.0%6,8826,8116,7376,6476,5226,4556,3376,1736,1176,0585,9695,8635,7475,6445,5935,5205,2905,2015,0915,0344,602
Shares Outstanding0.5%126126125125124124122121120118119117---------
Float----23,650---17,596---19,997---16,993---7,997-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-173.6%-81.51-29.79359-58.99-166-131-115-122-171-150-134-121-235-123-110-135-246-195-182289-188
  Share Based Compensation8.0%45.0042.0064.0076.0040.0043.0012830.0029.0045.0033.0032.0056.0034.0037.0034.0035.0066.0046.0031.0032.00
Cashflow From Investing71.9%-67.62-240-10.76-8.71-76.22-139314143-147-413-88.2715771.00-97.89-10.09-441114-220-10.08-289103
Cashflow From Financing-26.3%29.0039.0033.0053.0046.0063.0029730.0035.0029257433051.0021834.0068954.0040.00-20.70413391
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALNY Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 494,333$ 319,290
Operating costs and expenses:  
Cost of goods sold54,61341,432
Cost of collaborations and royalties11,36313,437
Research and development260,995230,569
Selling, general and administrative210,797183,659
Total operating costs and expenses537,768469,097
Loss from operations(43,435)(149,807)
Other (expense) income:  
Interest expense(35,253)(28,955)
Interest income29,64518,655
Other expense, net(14,544)(12,255)
Total other expense, net(20,152)(22,555)
Loss before income taxes(63,587)(172,362)
Provision for income taxes(2,348)(1,739)
Net loss$ (65,935)$ (174,101)
Net loss per common share - basic (in dollars per share)$ (0.52)$ (1.40)
Net loss per common share - diluted (in dollars per share)$ (0.52)$ (1.40)
Weighted-average common shares - basic (in shares)126,138124,111
Weighted-average common shares - diluted (in shares)126,138124,111
Statements of Comprehensive Loss  
Net loss$ (65,935)$ (174,101)
Other comprehensive (loss) income:  
Unrealized (loss) gain on marketable securities(3,568)4,125
Foreign currency translation (loss) gain(78)1,410
Defined benefit pension plans, net of tax33(5)
Total other comprehensive (loss) income(3,613)5,530
Comprehensive loss(69,548)(168,571)
Net product revenues  
Revenues:  
Total revenues365,163276,328
Net revenues from collaborations  
Revenues:  
Total revenues118,54836,462
Royalty revenue  
Revenues:  
Total revenues$ 10,622$ 6,500

ALNY Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 681,879$ 812,688
Marketable debt securities1,678,1471,615,516
Marketable equity securities11,25611,178
Accounts receivable, net321,377327,787
Inventory93,98889,146
Prepaid expenses and other current assets201,960126,382
Total current assets2,988,6072,982,697
Property, plant and equipment, net523,460526,057
Operating lease right-of-use assets195,468199,732
Restricted investments49,39049,391
Other assets67,46172,003
Total assets3,824,3863,829,880
Current liabilities:  
Accounts payable78,14855,519
Accrued expenses698,865713,013
Operating lease liability41,67241,510
Deferred revenue76,850102,753
Liability related to the sale of future royalties46,17454,991
Total current liabilities941,709967,786
Operating lease liability, net of current portion237,829243,101
Deferred revenue, net of current portion185,506188,175
Convertible debt1,021,7321,020,776
Liability related to the sale of future royalties, net of current portion1,336,8921,322,248
Other liabilities319,990308,438
Total liabilities4,043,6584,050,524
Commitments and contingencies (Note 13)
Stockholders’ deficit:  
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.01 par value per share, 250,000 shares authorized; 126,463 shares issued and outstanding as of March 31, 2024; 125,794 shares issued and outstanding as of December 31, 20231,2651,259
Additional paid-in capital6,881,9776,811,063
Accumulated other comprehensive loss(26,988)(23,375)
Accumulated deficit(7,075,526)(7,009,591)
Total stockholders’ deficit(219,272)(220,644)
Total liabilities and stockholders’ deficit$ 3,824,386$ 3,829,880
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEalnylam.com
 INDUSTRYBiotechnology
 EMPLOYEES2002

Alnylam Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Alnylam Pharmaceuticals Inc? What does ALNY stand for in stocks?

ALNY is the stock ticker symbol of Alnylam Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alnylam Pharmaceuticals Inc (ALNY)?

As of Fri May 17 2024, market cap of Alnylam Pharmaceuticals Inc is 18.9 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALNY stock?

You can check ALNY's fair value in chart for subscribers.

What is the fair value of ALNY stock?

You can check ALNY's fair value in chart for subscribers. The fair value of Alnylam Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alnylam Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALNY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alnylam Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ALNY is over valued or under valued. Whether Alnylam Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Alnylam Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALNY.

What is Alnylam Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ALNY's PE ratio (Price to Earnings) is -56.9 and Price to Sales (PS) ratio is 9.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALNY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alnylam Pharmaceuticals Inc's stock?

In the past 10 years, Alnylam Pharmaceuticals Inc has provided 0.106 (multiply by 100 for percentage) rate of return.